Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/112316
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, K. | - |
dc.contributor.author | Priebe, I. | - |
dc.contributor.author | Purins, L. | - |
dc.contributor.author | Tabor, B. | - |
dc.contributor.author | Brierley, G. | - |
dc.contributor.author | Lockett, T. | - |
dc.contributor.author | Nice, E. | - |
dc.contributor.author | Gibbs, P. | - |
dc.contributor.author | Tie, J. | - |
dc.contributor.author | McMurrick, P. | - |
dc.contributor.author | Moore, J. | - |
dc.contributor.author | Ruszkiewicz, A. | - |
dc.contributor.author | Burgess, A. | - |
dc.contributor.author | Cosgrove, L. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Cancer Biomarkers, 2013; 13(2):75-79 | - |
dc.identifier.issn | 1574-0153 | - |
dc.identifier.issn | 1875-8592 | - |
dc.identifier.uri | http://hdl.handle.net/2440/112316 | - |
dc.description.abstract | Background: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. Methods: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). Results: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort. Receiver operating characteristic analysis was performed to determine its performance as a diagnostic marker. The area under the curve was found to be 0.641 (95% confidence interval 0.576-0.706). Furthermore, the sensitivity of lipocalin 2 was found to be 24% at 90% specificity. Conclusions: Our study indicates that lipocalin 2 is not a suitable serum biomarker for the diagnosis of CRC. | - |
dc.description.statementofresponsibility | Kim Y.C. Fung, Ilka Priebe, Leanne Purins, Bruce Tabor, Gemma V. Brierley, Trevor Lockett, Edouard Nice, Peter Gibbs, Jeannie Tie, Paul McMurrick, James Moore, Andrew Ruszkiewicz , Antony Burgess and Leah J. Cosgrove | - |
dc.language.iso | en | - |
dc.publisher | IOS Press | - |
dc.rights | © 2013 – IOS Press and the authors. All rights reserved | - |
dc.source.uri | http://dx.doi.org/10.3233/cbm-130335 | - |
dc.subject | Colorectal cancer; biomarker; blood; diagnosis; lipocalin 2 | - |
dc.title | Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.3233/CBM-130335 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Ruszkiewicz, A. [0000-0001-9052-4948] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.